Therefore, we suggest that ouabain is involved in the progression of DLBCL by mediating m6A modification leading to RNA degradation, and ALKBH5/IGF2BP2 is a target molecule regulated by ouabain. The gene discussed is IGF2BP2; the disease is diffuse large B-cell lymphoma.